Selected Publications

The following 3 papers identify a novel enzyme (which we coined "cardiac sPLA2") and a mechanism whereby the heart modulates systemic inflammation and metabolism:

1. Berry E, Hernandez-Anzaldo S, Ghomashchi F, Lehner R, Murakami M, Gelb MH, Kassiri Z, Wang X, Fernandez-Patron C. Matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase a2 to modulate inflammation and fever. J Am Heart Assoc. 2015;4

2. Fernandez-Patron C, Leung D. Emergence of a metalloproteinase / phospholipase a2 axis of systemic inflammation. Metalloproteinases Med. 2015;2:29-38

3. Samuel Hernandez-Anzaldo EB, Vesna Brglez, Dickson Leung, Tae Jin Yun, Jun Seong Lee, Janos G Filep, Zamaneh Kassiri, Cheolho Cheong, Gérard Lambeau, Richard Lehner, and Carlos Fernandez-Patron. Identification of a novel heart/liver axis: Matrix metalloproteinases-2 negatively regulates cardiac secreted phospholipase a2 to modulate lipid metabolism and inflammation in the liver. J Am Heart Assoc. 2015;in press

The following 2 papers led to a new protein detection method marketed worldwide by various biotech companies:

1. Fernandez-Patron C, Castellanos-Serra L, Rodriguez P. Reverse staining of sodium dodecyl sulfate polyacrylamide gels by imidazole-zinc salts: Sensitive detection of unmodified proteins. Biotechniques. 1992;12:564-573

2. Fernandez-Patron C, Castellanos-Serra L, Hardy E, Guerra M, Estevez E, Mehl E, Frank RW. Understanding the mechanism of the zinc-ion stains of biomacromolecules in electrophoresis gels: Generalization of the reverse-staining technique. Electrophoresis. 1998;19:2398-2406

The following 7 papers describe novel functions of MMPs in cardiovascular function:

1. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906-911

2. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res. 2000;87:670-676

3. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res. 2004;94:68-76

4. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan BA, Schulz R, Kassiri Z, Lopaschuk GD, Fernandez-Patron C. Matrix metalloproteinase-7 and adam-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation. 2009;119:2480-2489

5. Bosonea AM, Wang X, Odenbach J, Fernandez-Patron C. Metalloproteinases in hypertension and cardiac disease: Differential expression and mutual regulation. Drug Discov Today Dis Models. 2011;8:29-35

6. Fernandez-Patron C, Filep JG. Gpcrs in cardiovascular pathologies. Drug Discov Today Dis Mech. 2012;9:e75-e78

7. Wang X, Bosonea AM, Fernandez-Patron C. Metalloproteinases: Key and common mediators of multiple gpcrs and candidate therapeutic targets in models of hypertensive cardiac disease. Drug Discov Today Dis Models. 2012;9:e103-e108